Overview

Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Alliance for Clinical Trials in Oncology

Collaborator:

National Cancer Institute (NCI)

Treatments:

Carboplatin
Docetaxel
Estramustine
Hormones
Lenograstim